Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.

CP-724,714, a potent and selective orally active HER2 tyrosine kinase inhibitor, was discontinued from clinical development due to unexpected hepatotoxicity in cancer patients. Based on the clinical manifestation of the toxicity, CP-724,714 likely exerted its hepatotoxicity via both hepatocellular injury and hepatobiliary cholestatic mechanisms. The direct cytotoxic effect, hepatobiliary disposition of CP-724,714, and its inhibition of active canalicular transport of bile constituents were evaluated in established human hepatocyte models and in vitro transporter systems. CP-724,714 exhibited direct cytotoxicity using human hepatocyte imaging assay technology with mitochondria identified as a candidate organelle for its off-target toxicity. Additionally, CP-724,714 was rapidly taken up into human hepatocytes, partially via an active transport process, with an uptake clearance approximately fourfold higher than efflux clearance. The major human hepatic uptake transporter, OATP1B1, and efflux transporters, multidrug resistance protein 1 (MDR1) and breast cancer resistance protein, were involved in hepatobiliary clearance of CP-724,714. Furthermore, CP-724,714 displayed a concentration-dependent inhibition of cholyl-lysyl fluorescein and taurocholate (TC) efflux into canaliculi in cryopreserved and fresh cultured human hepatocytes, respectively. Likewise, CP-724,714 inhibited TC transport in membrane vesicles expressing human bile salt export pump with an IC(50) of 16 microM. Finally, CP-724,714 inhibited the major efflux transporter in bile canaliculi, MDR1, with an IC(50) of approximately 28 microM. These results suggest that inhibition of hepatic efflux transporters contributed to hepatic accumulation of drug and bile constituents leading to hepatocellular injury and hepatobiliary cholestasis. This study provides likely explanations for clinically observed adverse liver effects of CP-724,714.

[1]  R. Kim.  Transporters and drug discovery: why, when, and how. , 2006, Molecular pharmaceutics.

[2]  D. Keppler,et al.  cDNA Cloning of the Hepatocyte Canalicular Isoform of the Multidrug Resistance Protein, cMrp, Reveals a Novel Conjugate Export Pump Deficient in Hyperbilirubinemic Mutant Rats* , 1996, The Journal of Biological Chemistry.

[3]  R. D. Connell,et al.  Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. , 2007, Cancer research.

[4]  X Liu,et al.  Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[5]  D. B. Duignan,et al.  A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. , 2006, Molecular pharmaceutics.

[6]  Richard J. Thompson,et al.  The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. , 2002, Gastroenterology.

[7]  Tsuyoshi Mikkaichi,et al.  The organic anion transporter (OATP) family. , 2004, Drug metabolism and pharmacokinetics.

[8]  D. Keppler,et al.  Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6* , 2001, The Journal of Biological Chemistry.

[9]  H. Kusuhara,et al.  FUNCTIONAL INVOLVEMENT OF RAT ORGANIC ANION TRANSPORTER 2 (SLC22A7) IN THE HEPATIC UPTAKE OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG KETOPROFEN , 2005, Drug Metabolism and Disposition.

[10]  P. Meier,et al.  Hepatobiliary transporters and drug‐induced cholestasis , 2006, Hepatology.

[11]  Peter V. Henstock,et al.  Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  S. Strom,et al.  Transport, metabolism, and hepatotoxicity of flutamide, drug-drug interaction with acetaminophen involving phase I and phase II metabolites. , 2007, Chemical research in toxicology.

[13]  D. Keppler,et al.  Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in dubin‐johnson syndrome , 2000, Hepatology.

[14]  S. Strautnieks,et al.  BSEP: Function and Role in Progressive Familial Intrahepatic Cholestasis , 2001, Seminars in liver disease.

[15]  S. D. de Morais,et al.  Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. , 2004, Chemico-biological interactions.

[16]  A. Hofmann.  Biliary secretion and excretion in health and disease: current concepts. , 2007, Annals of hepatology.

[17]  Bo Feng,et al.  In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.

[18]  C. Klaassen.  Comparison of the toxicity of chemicals in newborn rats to bile duct-ligated and sham-operated rats and mice. , 1973, Toxicology and applied pharmacology.

[19]  J. Marin,et al.  Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. , 2006, Journal of hepatology.

[20]  K. Gelmon,et al.  First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors , 2007, Clinical Cancer Research.

[21]  H. Kotaki,et al.  Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[22]  K. Maeda,et al.  Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.

[23]  Bo Feng,et al.  Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human , 2007, Drug Metabolism and Disposition.

[24]  Richard J. Thompson,et al.  Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. , 1999, Gastroenterology.

[25]  Diana Kazolias,et al.  Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport , 2006, Drug Metabolism and Disposition.

[26]  Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety , 2008, Cancer Chemotherapy and Pharmacology.

[27]  Philip Zocharski,et al.  Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[28]  J. Houston,et al.  Uptake and Intracellular Binding of Lipophilic Amine Drugs by Isolated Rat Hepatocytes and Implications for Prediction of in Vivo Metabolic Clearance , 2006, Drug Metabolism and Disposition.

[29]  A. Kalgutkar,et al.  Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[31]  Bruno Stieger,et al.  Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[32]  J. Boyer.  A biliary milestone: functional expression of the human bile salt export pump. , 2002, Gastroenterology.